![]() |
Name |
Methyl 10-methylundecanoate
|
Molecular Formula | C13H26O2 | |
IUPAC Name* |
methyl 10-methylundecanoate
|
|
SMILES |
CC(C)CCCCCCCCC(=O)OC
|
|
InChI |
InChI=1S/C13H26O2/c1-12(2)10-8-6-4-5-7-9-11-13(14)15-3/h12H,4-11H2,1-3H3
|
|
InChIKey |
XPVCTJYIICVJOE-UHFFFAOYSA-N
|
|
Synonyms |
Methyl 10-methylundecanoate; 5129-56-6; 10-Methylundecanoic acid methyl ester; Undecanoic acid, 10-methyl-, methyl ester; Methyl 10-methylundecanoate #; SCHEMBL1369686; DTXSID20339162; ZINC2515955; Q63395942
|
|
CAS | 5129-56-6 | |
PubChem CID | 554144 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 214.34 | ALogp: | 5.5 |
HBD: | 0 | HBA: | 2 |
Rotatable Bonds: | 10 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 26.3 | Aromatic Rings: | 0 |
Heavy Atoms: | 15 | QED Weighted: | 0.415 |
Caco-2 Permeability: | -4.448 | MDCK Permeability: | 0.00002040 |
Pgp-inhibitor: | 0.212 | Pgp-substrate: | 0.003 |
Human Intestinal Absorption (HIA): | 0.002 | 20% Bioavailability (F20%): | 0.938 |
30% Bioavailability (F30%): | 0.948 |
Blood-Brain-Barrier Penetration (BBB): | 0.886 | Plasma Protein Binding (PPB): | 95.22% |
Volume Distribution (VD): | 0.662 | Fu: | 3.44% |
CYP1A2-inhibitor: | 0.931 | CYP1A2-substrate: | 0.467 |
CYP2C19-inhibitor: | 0.699 | CYP2C19-substrate: | 0.615 |
CYP2C9-inhibitor: | 0.638 | CYP2C9-substrate: | 0.948 |
CYP2D6-inhibitor: | 0.021 | CYP2D6-substrate: | 0.068 |
CYP3A4-inhibitor: | 0.259 | CYP3A4-substrate: | 0.147 |
Clearance (CL): | 7.745 | Half-life (T1/2): | 0.545 |
hERG Blockers: | 0.049 | Human Hepatotoxicity (H-HT): | 0.049 |
Drug-inuced Liver Injury (DILI): | 0.262 | AMES Toxicity: | 0.006 |
Rat Oral Acute Toxicity: | 0.036 | Maximum Recommended Daily Dose: | 0.017 |
Skin Sensitization: | 0.932 | Carcinogencity: | 0.139 |
Eye Corrosion: | 0.949 | Eye Irritation: | 0.97 |
Respiratory Toxicity: | 0.696 |